Program
iPSC-derived Allogeneic Anti-CD19 1XX-CAR T-cells FT819
Its studies are mostly in Lupus Nephritis · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis · Lymphoma, B-Cell, led by Fate Therapeutics.
Drug pageIPSC-derived Allogeneic Anti-CD19 1XX-CAR T-cells FT819: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.Furthest: phase 2, since Apr 30, 20263 company-led studies, 3 open or runningNext primary completion: Sep 30, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Fate Therapeutics | 33 open or running | phase 2since Apr 30, 2026 | Nov 10, 2020 | Sep 30, 2027phase 1 · NCT06308978 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 10, 2020First study: phase 1 study in Lymphoma, B-CellFirst studyNCT04629729 · 54 enrolled · United States
- Mar 6, 2024Phase 1 study in Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisNCT06308978 · 244 planned · United States, France, Sweden and more
- Apr 30, 2026Phase 2 study in Lupus NephritisPhase 2 reachedNCT07570862 · 53 planned · United States
Ahead
- Sep 30, 2027Primary completion: phase 1 study in Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisNCT06308978
- Jul 1, 2029Primary completion: phase 2 study in Lupus NephritisNCT07570862
TargetBeta
CD19 →read by rule
“A preparation of off-the-shelf (OTS) T-lymphocytes, generated from an induced pluripotent stem cell (iPSC) line, that have been genetically modified to express a CD19 1XX chimeric antigen receptor (CAR) that targets the tumor-associated antigen (TAA) CD19, ”NCIt, by rule
Other programs on CD19
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| blinatumomabrule | Amgen | phase 4 | 29 |
| inebilizumabrule | Amgen | phase 4 | 19 |
| Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F | AstraZeneca | phase 3 | 12 |
| axicabtagene ciloleucelrule | Gilead Sciences | phase 3 | 10 |
| surovatamig | AstraZeneca | phase 3 | 10 |
| lisocabtagene maraleucelrule | Bristol-Myers Squibb | phase 3 | 10 |
| Anti-CD19/CD3 Bispecific Antibody MK-1045 | Merck | phase 3 | 8 |
| obexelimab | zenas-biopharma-usa-llc | phase 3 | 7 |
| Autologous Anti-CD19 CAR-T Cells CABA-201rule | cabaletta-bio | phase 3 | 6 |
| zolacabtagene autoleucel | Bristol-Myers Squibb | phase 3 | 6 |
| Autologous Anti-CD19/Anti-CD20 CAR-T Cells KITE-753rule | Gilead Sciences | phase 3 | 2 |
| rondecabtagene autoleucelrule | lyell-immunopharma-inc | phase 3 | 2 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07570862Lupus Nephritis · United States | 2 | Recruiting | Jul 1, 2029 | 53 |
| NCT06308978Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis · United States, France, Sweden and more | 1 | Recruiting | Sep 30, 2027 | 244 |
| NCT04629729Lymphoma, B-Cell · United States | 1 | Active, not recruiting | Jun 18, 2025 | 54 |
How it is read
Names in the registry
- “FT819”, 3 entries
Conditions, from the studies’ own filings
- Lupus Nephritis, 1 study
- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, 1 study
- Lymphoma, B-Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.